Given the increasing commodization of their insulin franchise Novo Nordisk increasingly has relied on their GLP-1 portfolio to drive sales and profits. With the oral version of semaglutide now at the FDA and approval expected before the end of the year many have projected blockbuster potential for this first ever orally delivered GLP-1. As we have noted in past writings on this drug, we anticipate a strong start but are concerned over the longer term given the drugs rather complex dosing regimen.
As it turns out the drug may have another hurdle to overcome as according to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.